Highlights Aclarion, Inc.

Equities

ACON

US6551872012

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-31 EDT			5-day change	1st Jan Change
0.3 ^USD	-3.54%		-4.00%	-90.62%

05-26	Certain Warrants of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	CI
05-26	Certain Stock Options of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-21	CI
Aclarion Announces Updated Product Release That Expands Mri Scanner Access for Nociscan Solution	01-17	CI
Aclarion and Atec Execute Strategic Partnership Agreement to Advance Commercialization of Nociscan	01-08	CI
Aclarion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Aclarion to Form Partnership With Alphatec Holdings Unit to Accelerate Marketing of Nociscan	23-10-23	MT
Aclarion Announces Signing Strategic Partnership Letter of Intent With ATEC to Advance Commercialization of Nociscan	23-10-23	CI
Aclarion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-07-03	CI
Aclarion Signs Commercial Deal With Michigan Medical Imaging Center	23-06-14	MT
ACLARION, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	23-02-27	AQ
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
ACLARION, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-14	AQ
Aclarion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Aclarion, Inc.'s Nociscan Selected for Inclusion in Pivotal National Institutes of Health Study for Low Back Pain	22-09-19	CI
ACLARION, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-15	AQ
Aclarion : to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain	22-06-22	PU
ACLARION, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-06-06	AQ
Aclarion Closes $9.4 Million IPO	22-04-27	MT
Aclarion Prices $9.4 Million IPO	22-04-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aclarion, Inc.

Equities

ACON

US6551872012

Highlights

Filters